Loading organizations...
Key people at Sairopa B.V..
Sairopa B.V. develops novel cancer treatments through precise modulation of the patient’s immune system. Its core product candidates include ADU-1805, an anti-SIRPalpha antibody enhancing tumor cell uptake and T cell presentation, and ADU-1604, an anti-CTLA4 antibody boosting T cell priming and activation. This strategic approach targets specific points within the cancer-immunity cycle for robust anti-cancer immune responses.
Established in early 2021, Sairopa acquired its foundational therapeutic antibody portfolio from Chinook Therapeutics, supported by Van Herk Investments. Founders Dharminder Singh Chahal and Gurvinder Singh Chahal launched the company, driven by an insight into existing immunotherapy limitations. They focused on developing agents activating a broader range of immune mechanisms for patients unresponsive to current treatments.
Sairopa’s therapies are intended for cancer patients, with ADU-1604 currently in Phase 1 clinical trials for advanced melanoma. The company's mission is to advance these precision agents through clinical development. By strategically intervening in the immune system, Sairopa aims to deliver significant clinical benefits and improve outcomes for a wider population of cancer patients.
Key people at Sairopa B.V..
Sairopa B.V. is a clinical-stage biotech company headquartered in Rotterdam, Netherlands, focused on developing novel cancer immunotherapies by modulating the patient's immune system to enhance anti-tumor responses.[1][3][8] Its pipeline includes ADU-1805 (anti-SIRPα antibody in Phase 1 for advanced solid tumors), ADU-1604 (anti-CTLA4 antibody, Phase 1 completed for PD-1 relapsed/refractory melanoma with Phase 2 planned for 2025), and a preclinical SIRPαxPD-L1 bispecific antibody targeting an IND filing in 2026.[1][3][7] The company serves oncology patients with hard-to-treat cancers, addressing immune suppression mechanisms that limit current therapies' efficacy, and demonstrates growth through partnerships like a $40M upfront and $35M milestone from Exelixis in 2024.[3][7]
Incorporated in 2021 and backed by Van Herk Investments, Sairopa has advanced rapidly, acquiring key assets and achieving clinical milestones that validate its proprietary antibody platforms.[2][5][6]
Sairopa B.V. was incorporated in 2021 in Rotterdam, Netherlands, entering the cancer immunotherapy space through a strategic acquisition backed by Van Herk Investments, a life sciences-focused investor.[2][5][6] In April 2021, Sairopa purchased a portfolio of non-renal therapeutic antibodies from Chinook Therapeutics, Inc., including assets originally from BioNovion/Aduro Biotech, which propelled it into clinical development.[5][6] This move followed Novartis's 2023 acquisition of Chinook for renal assets, leading to the divestment of Sairopa shares, which Van Herk Investments fully acquired in March 2024 to sustain momentum.[5]
The company's emergence capitalized on prior research into immune-modulating antibodies like anti-SIRPα (e.g., Voets et al., 2019), transforming preclinical promise into a robust pipeline with early clinical traction, including Phase 1 initiations and partnership deals.[3][6]
Sairopa rides the wave of next-generation immunotherapy, targeting "don't eat me" signals like SIRPα to overcome resistance in solid tumors, a key trend as PD-1 inhibitors plateau in efficacy for many cancers.[1][3] Timing aligns with surging demand for combo-immune therapies amid a post-2020 biotech resurgence in antibody engineering, bolstered by AI-driven discovery and bispecifics.[1][7] Market forces favor it: rising incidence of immunotherapy-resistant neoplasms, investor interest in clinical-stage assets (e.g., Van Herk's life sciences portfolio), and Big Pharma scouting (Exelixis option).[3][5][7] Sairopa influences the ecosystem by licensing proven assets to accelerate validation, potentially expanding Dutch biotech's global footprint in oncology.[5]
Sairopa's trajectory points to Phase 2 readouts for ADU-1604 in 2025 and IND for its bispecific in 2026, with Exelixis's option decision hinging on Phase 1 data—success could trigger licensing and commercialization.[3][7] Trends like bispecific antibodies and combo regimens will shape its path, amplifying impact if partnerships scale. Its influence may grow via Van Herk support, positioning it as a nimble player in immune-oncology innovation, much like its origin acquisition turned dormant assets into clinical contenders.[5][6]
